Loading...
XNASJAZZ
Market cap7.43bUSD
Dec 20, Last price  
122.97USD
1D
0.10%
1Q
11.02%
Jan 2017
12.79%
IPO
164.11%
Name

Jazz Pharmaceuticals PLC

Chart & Performance

D1W1MN
XNAS:JAZZ chart
P/E
17.92
P/S
1.94
EPS
6.86
Div Yield, %
0.00%
Shrs. gr., 5y
3.32%
Rev. gr., 5y
15.19%
Revenues
3.83b
+4.78%
021,442,00044,856,00065,303,00067,514,000128,449,000173,781,000272,277,000585,979,000872,423,0001,172,875,0001,324,803,0001,487,973,0001,618,693,0001,890,922,0002,161,761,0002,363,567,0003,094,238,0003,659,374,0003,834,204,000
Net income
415m
P
-24,804,000-85,156,000-59,391,000-138,826,000-184,339,000-6,836,00032,778,000124,984,000288,586,000216,312,00058,387,000329,535,000396,831,000487,848,000447,098,000523,367,000238,616,000-328,954,000-214,139,000414,832,000
CFO
1.09b
-14.15%
-52,162,000-57,350,000-81,091,000-130,232,000-15,878,00058,868,000151,596,000249,752,000283,616,000405,765,000531,943,000590,536,000693,087,000798,904,000776,401,000899,648,000778,507,0001,271,977,0001,092,007,000
Earnings
Feb 25, 2025

Profile

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Zepzelca for the treatment of adult patients with metastatic small cell lung cancer. The company also offers Xywav, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for narcolepsy patients; JZP385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and JZP150 for treatment of post-traumatic stress disorder. The company has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; XL-protein GmbH; and Redx Pharma plc. Jazz Pharmaceuticals plc was incorporated in 2003 and is headquartered in Dublin, Ireland.
URL
https://www.jazzpharma.com/
IPO date
Jan 18, 2012
Employees
2,800
Domiciled in
IE
Incorporated in
IE

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
3,834,204
4.78%
3,659,374
18.26%
3,094,238
30.91%
Cost of revenue
1,285,235
1,130,970
946,508
Unusual Expense (Income)
NOPBT
2,548,969
2,528,404
2,147,730
NOPBT Margin
66.48%
69.09%
69.41%
Operating Taxes
(119,912)
(158,645)
216,116
Tax Rate
10.06%
NOPAT
2,668,881
2,687,049
1,931,614
Net income
414,832
-293.72%
(214,139)
-34.90%
(328,954)
-237.86%
Dividends
Dividend yield
Proceeds from repurchase of equity
(269,761)
97,966
99,659
BB yield
3.04%
-0.98%
-1.31%
Debt
Debt current
624,401
31,000
31,000
Long-term debt
5,245,885
5,837,017
6,193,343
Deferred revenue
5,039
463
Other long-term liabilities
104,751
106,812
116,998
Net debt
4,239,276
4,981,035
5,620,866
Cash flow
Cash from operating activities
1,092,007
1,271,977
778,507
CAPEX
(23,962)
(498,194)
(45,532)
Cash from investing activities
(163,062)
(446,230)
(5,212,143)
Cash from financing activities
(305,254)
(529,491)
3,970,522
FCF
2,533,923
3,108,713
972,079
Balance
Cash
1,626,310
881,482
591,448
Long term investments
4,700
5,500
12,029
Excess cash
1,439,300
704,013
448,765
Stockholders' equity
36,570
(391,862)
429,927
Invested Capital
9,596,792
9,372,870
9,780,260
ROIC
28.14%
28.06%
26.23%
ROCE
24.32%
25.47%
18.66%
EV
Common stock shares outstanding
72,066
62,539
59,694
Price
123.00
-22.79%
159.31
25.05%
127.40
-22.81%
Market cap
8,864,118
-11.03%
9,963,088
31.01%
7,605,016
-18.47%
EV
13,103,394
14,944,123
13,225,882
EBITDA
3,187,665
3,157,875
2,700,213
EV/EBITDA
4.11
4.73
4.90
Interest
289,438
288,242
278,766
Interest/NOPBT
11.36%
11.40%
12.98%